ReFocus: A Phase 1/2 Study of the Highly Selective FGFR2 Inhibitor, RLY-4008, in Patients with Advanced Solid Tumors Including Breast Cancer

被引：0
|
作者：
Kamath, Suneel
Tai, David
Moreno, Irene
Babiker, Hani
Jin, Zhaohui
Yoo, Changhoon
Ricard, Fabien
Jen, Kai Yu
Coward, Jim
Liu, Jia
Opdam, Frans
Millward, Michael
Ponz-Sarvise, Mariano
Yachnin, Jeffrey
Kim, Richard
Park, Joon Oh
Subbiah, Vivek
Schram, Alison M.
机构：
来源：
CANCER RESEARCH | 2023年 / 83卷 / 05期
关键词：
D O I：
10.1158/1538-7445.SABCS22-OT3-24-01
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
OT3-24-01
引用
收藏
页数：3
相关论文
共 50 条
  • [31] Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors
    Delord, Jean-Pierre
    Italiano, Antoine
    Awada, Ahmad
    Aftimos, Philippe
    Houede, Nadine
    Lebbe, Celeste
    Pages, Celine
    Lesimple, Thierry
    Dinulescu, Monica
    Schellens, Jan H. M.
    Leijen, Suzanne
    Rottey, Sylvie
    Kruse, Vibeke
    Kefford, Richard
    Faivre, Sandrine
    Gomez-Roca, Carlos
    Scheuler, Armin
    Massimini, Giorgio
    Raymond, Eric
    TARGETED ONCOLOGY, 2021, 16 (01) : 37 - 46
  • [32] Selective Oral MEK1/2 Inhibitor Pimasertib: A Phase I Trial in Patients with Advanced Solid Tumors
    Jean-Pierre Delord
    Antoine Italiano
    Ahmad Awada
    Philippe Aftimos
    Nadine Houédé
    Céleste Lebbé
    Celine Pages
    Thierry Lesimple
    Monica Dinulescu
    Jan H. M. Schellens
    Suzanne Leijen
    Sylvie Rottey
    Vibeke Kruse
    Richard Kefford
    Sandrine Faivre
    Carlos Gomez-Roca
    Armin Scheuler
    Giorgio Massimini
    Eric Raymond
    Targeted Oncology, 2021, 16 : 37 - 46
  • [33] First-in-human phase I study of a selective VEGFR/FGFR dual inhibitor sulfatinib in patients with advanced solid tumors.
    Xu, Jian-Ming
    Wang, Yan
    Shen, Lin
    Gong, Jifang
    Huang, Cheng
    Ye, Chen Yang
    Yang, Li
    Sai, Yang
    Mu, Hua
    JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [34] Enfortumab vedotin 202: Phase 2 study of enfortumab vedotin for previously treated advanced solid tumors, including breast cancer
    Ono, Makiko
    Bruce, Justine Yang
    Feinstein, Trevor
    Muro, Kei
    Derleth, Christina
    Gorla, Seema
    Wu, Chunzhang
    Novik, Yelena
    CANCER RESEARCH, 2022, 82 (04)
  • [35] NVL-520, a Highly Selective ROS1 Inhibitor, in Patients with Advanced ROS1-Positive Solid Tumors: The Phase 1/2 ARROS-1 Study
    Drilon, A.
    Ou, S. -H. I.
    Gadgeel, S.
    Johnson, M.
    Spira, A.
    Lopes, G.
    Besse, B.
    Felip, E.
    van der Wekken, A. J.
    Calles, A.
    de Miguel, M. J.
    Camidge, D. R.
    Elamin, Y.
    Liu, S.
    Bauman, J.
    Haggstrom, D.
    Riley, G.
    Pelish, H. E.
    Zhu, V. W.
    Lin, J. J.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S416 - S416
  • [36] Effect of dose level of the selective FGFR2 inhibitor alofanib on toxicity, pharmacokinetics and preliminary efficacy: A phase Ib study in patients with advanced gastric cancer (RPT835GC1B)
    Tsimafeyeu, I.
    Kazey, V.
    Dragun, N.
    Reznikov, D.
    Gavrilova, E.
    Gorbacheva, S.
    Nikiforova, A.
    Byakhov, M.
    Tjulandin, S.
    ANNALS OF ONCOLOGY, 2021, 32 : S16 - S17
  • [37] Phase 2 study of futibatinib in patients with gastric or gastroesophageal junction cancer harboring FGFR2 amplifications
    Satoh, Taroh
    Barthelemy, Philippe
    Nogova, Lucia
    Honda, Kazunori
    Hirano, Hidekazu
    Lee, Keun-Wook
    Rha, Sun Young
    Ryu, Min-Hee
    Park, Joon Oh
    Doi, Toshihiko
    Ajani, Jaffer
    Hangai, Nanae
    Kremer, Jill
    Mina, Mark
    Liu, Mei
    Shitara, Kohei
    EUROPEAN JOURNAL OF CANCER, 2025, 218
  • [38] A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer
    Michael Michael
    Yung-Jue Bang
    Young Suk Park
    Yoon-Koo Kang
    Tae Min Kim
    Oday Hamid
    Donald Thornton
    Sonya C. Tate
    Eyas Raddad
    Jeanne Tie
    Targeted Oncology, 2017, 12 : 463 - 474
  • [39] First-in-human global study of RLY-2608, a panmutant and isoform selective PI3Ka inhibitor, as a single agent in patients with advanced solid tumors and in combination with fulvestrant in patients with advanced breast cancer
    Varkaris, Andreas
    Jhaveri, Komal
    Cabanas, Elena Garralda
    Sanz, Lucia
    Kim, Janice
    Perez, Cesar A.
    Hamilton, Erika
    Spira, Alexander I.
    Wisinski, Kari
    Guerrero, Angel
    Henry, Jason
    Ahnert, Jordi Rodon
    Tan, Gege
    Li, Xiaoyan
    Hummel, Diana
    Hunter, Tamieka
    Timm, Alison
    Samadani, Ramin
    Puente-Poushnejad, Erika
    Kwak, Eunice
    Mar, Brenton G.
    Schram, Alison M.
    CANCER RESEARCH, 2024, 84 (09)
  • [40] A Phase 1 Study of LY2874455, an Oral Selective pan-FGFR Inhibitor, in Patients with Advanced Cancer
    Michael, Michael
    Bang, Yung-Jue
    Park, Young Suk
    Kang, Yoon-Koo
    Kim, Tae Min
    Hamid, Oday
    Thornton, Donald
    Tate, Sonya C.
    Raddad, Eyas
    Tie, Jeanne
    TARGETED ONCOLOGY, 2017, 12 (04) : 463 - 474
12345